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Abstract
Background: Increasing recognition of Attention Deficit Hyperactivity Disorder (ADHD) among Aboriginal children,
adolescents and young adults is a public health challenge. We investigated the pattern of prescription stimulants
for ADHD among Aboriginal individuals in Western Australia (WA).
Methods: Using a whole-population-based linked data we followed a cohort of individuals born in WA from
1980–2005, and their parents were born in Australia, to identify stimulant prescription for ADHD derived from
statutory WA stimulant prescription dispensing between 2003 and 2007. Parental link was ascertained through
WA Family Connections Genealogical Linkage System. Cox proportional hazards regression (HR) models were
performed to determine the association between stimulant use and Aboriginal and non-Aboriginal status.
Results: Of the total cohort of 186,468, around 2 % (n = 3677) had prescription stimulants for ADHD. Individuals with
both Aboriginal parents were two-thirds (HR 0.33, 95 % CI 0.26–0.42), and with only Aboriginal mother were one-third
(HR 0.69, 95 % CI 0.53–0.90) less likely to have stimulants, compared to individuals with non-Aboriginal parents. HR in
Aboriginals was 62 % lower (HR 0.35, 95 % CI 0.25–0.49) in metropolitan areas, and 72 % lower (HR 0.28,
95 % CI 0.20–0.38) in non-metropolitan areas, than non-Aboriginals. The risk for simulant use was four times
higher among Aboriginal boys than Aboriginal girls (HR 4.08, 95 % CI, 2.92–5.69).
Conclusion: Aboriginal cultural understanding of ADHD and attitude towards stimulant medication serve as
a determinant of their access to health services. Any ADHD intervention and policy framework must take into
account a holistic approach to Aboriginal culture, beliefs and individual experience to provide optimal care
they need.
Background
Attention Deficit Hyperactivity Disorder (ADHD) has
been defined as a common childhood-onset neurodeve-
lopmental disorder characterized by severe inattention,
impulsivity and hyperactivity which can be associated
with significant educational and social impairment [1].
Psychostimulant medications such as methylphenidate
and dexamphetamine are often recommended as a first-
line modality for treating ADHD [2]. Despite extensive
research into factors contributing to ADHD, the
aetiology and pathogenesis of the condition are poorly
understood. It may be influenced by a combination of
genetic and environmental factors [3–5]. As is true with
most mental and developmental disorders, there is not a
definitive test for ADHD, because diagnosis and classifi-
cation primarily rely on observed or self-reported behav-
iours. Moreover, the interpretations of the severity of
those behaviours and whether they should be described
as abnormal are subjective [6].
In Australia, there has been an increasing recognition
of ADHD symptoms among Aboriginal children and ad-
olescents than those in the non-Aboriginal population.
Zubrick et al. [7] identified 15 % Aboriginal children
compared to 9.7 % non-Aboriginals at the same age were
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at high risk of clinically significant hyperactivity. Yet, we
do not have a clear understanding of the determinants
that may account for this disparity. People with ADHD
are over-represented in criminal justice system [8], and
the rates of incarceration are reported high among Abo-
riginal young [9]. The prevalence of ADHD is higher
among people living in low socioeconomic condition
[10, 11]. It is well established that Aboriginal children
are socially and economically disadvantaged with a lower
life expectancy and less than equal opportunity. Whether
the higher manifestation of ADHD symptoms in Abori-
ginal children and adolescents is a true prevalence of
clinical ADHD, or their unique learning and behavioural
patterns [12] that may erroneously lead to ADHD diag-
nosis pause a question.
There remains a dearth of research examining the
degree to which ADHD behaviour is perceived as a
problem and stimulant treatment is sought for ADHD in
Aboriginal communities. Aboriginals place a holistic
concept of mental illness including culture and spiritual-
ity, family and community kinships, historical, social and
economic factors, fear, education and loss [13] which
may construct a different attitude towards Western bio-
medical diagnostic labels and treatment for ADHD
behaviour to that of mainstream Australians. This study
reports the first whole-population-based Australian
study of prescription stimulant pattern for ADHD
among Aboriginals. In this paper the term “Aboriginal”
encompasses both Aboriginal and Torres Strait Islanders




The study population comprised a retrospective cohort
of all children, adolescents and young adults who were
born in WA from 1980–2005, and their parents were
born in Australia, and were stratified by their parents’
Aboriginal and non-Aboriginal status. The cohort was
then followed through to identify their first com-
mencement of prescription stimulant for ADHD be-
tween 2003 and 2007. Records for still-births, parents
born overseas, unknown/missing Aboriginal identity
and death before 2003 were excluded, leaving 186,468
individuals for analysis. The selection criteria and
process are shown in Fig. 1.
Data sources
Data were extracted from the WA Register of Birth,
Death Registry, Midwives’ Notification System (MNS)
and Monitoring of Drugs of Dependence Systems
through WA Data Linkage System which links databases
using probabilistically matching techniques [15], and is
known to achieve high level of linkage sensitivity (95–
99 %) and specificity (98–99 %) [16]. The WA Family
MODDS= Monitoring of Drugs of Dependence System
Birth Registration 1980-2005
n=635,858
Exclusions (not mutually exclusive)
- died before 2003: n=8,750
- still birth: n=1,272
- parents born overseas: n=283,666















Linking Death Registration 1980-2003
Fig. 1 Aboriginal and non-Aboriginal cohort identification, group selection and exclusion criteria
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Connections Genealogical Database was linked to ascer-
tain parent–child relationships [17].
Variables and measurements
The outcome measure was at least one record of prescrip-
tion stimulant (methylphenidate and/or dexamphetamine)
dispensing for ADHD at any time during 2003–2007. Data
was collected on a range of demographic factors including
sex, Aboriginality, geographical remoteness, socioeconomic
disadvantage and mother’s age. Parents’ Aboriginal status
based on self-identification was derived from birth registry
and MNS. The birth registry collects Aboriginal status of
both parents, while the MNS collects information of the
mothers only. Parents were recorded in birth registry as
‘Aboriginal’ ‘Aboriginal/TSI’, ‘Torres Strait Islander’, ‘Yes
Aboriginal’, ‘Not Aboriginal’, ‘unknown’, and MNS data was
coded as ‘Aboriginal/TSI’, ‘Caucasian’ and ‘other’. For this
analysis all ‘Aboriginal’ and ‘Torres Strait Islander’ records
were referred to as Aboriginal; and ‘Caucasian’, ‘Not Abori-
ginal’ and ‘other’ records as non-Aboriginal. Aboriginal
people are known to be under-identified or misidentified
due to the fact that people may not be prepared to disclose
their Aboriginal status depending on the situation [18].
Therefore, parents was considered Aboriginal if they had at
least one record showing as an Aboriginal/or Torres Strait
Islander in either birth registry or MNS datasets. As such,
a parent, identified as Aboriginal in one dataset and non-
Aboriginal in the other, was considered as Aboriginal to
maximise reporting of Aboriginal people in this study [19].
Geographical remoteness was measured using the Ac-
cessibility/Remoteness Index of Australia (ARIA) [20] of
the Australian Census, using whichever of the 1996,
2001 or 2006 indices were closest to the year of cohort
entry. ARIA scores were grouped into three levels:
metropolitan, rural and remote, with metropolitan used
as the reference category indicating high accessibility
according to residential postcode at the time of birth.
Socioeconomic disadvantage was ascertained according
to the Index of Relative Socio-Economic Disadvantage
(IRSD), a summary measure of Socio-Economic Indexes
for Areas (SEIFA) that focused on disadvantage in terms
of accessibility to education, employment and income
[21]. The IRSD scores were then groups into quintiles
ranging from most disadvantaged to least disadvantaged.
Similar to ARIA, SEIFA score was derived from the
national census years 1996, 2001, or 2006, using the
index closest to the time of birth.
Statistical analysis
Descriptive statistics were calculated for all baseline
demographic characteristics of the study sample, strati-
fied by stimulant use group. The associations between
stimulant use and potential predictors including
gender, age, Aboriginality, geographical remoteness and
socioeconomic disadvantage were investigated using uni-
variate and multivariate Cox proportional hazards
regression (HR) models with a follow-up time 31 of
December 2007. Multiple linear regression models were
also fitted to compare ages of individuals at initial stimu-
lant use during 2003–2007. A two-sided p-value of <0.05
was considered statistically significant in all analyses.
Missing values for each variable were entered as a separ-
ate exposure category in order to include all subjects in
the analyses. Statistical analyses were performed with
SPSS statistical software version 21.0.
Ethics approval
The study protocol adhered to guidelines for ethical
conduct of Aboriginal health research, and was approved
by the WA Aboriginal Health Ethics Committee (Ref.no.
589), Human Research Ethics Committee of University
of WA (Ref.no. RA/4/1/2000), and Department of
Health WA Human Research Ethics Committee (Ref.no.
2008/25). As de-identified data was utilised in this study,
individual consent was not required.
Results
Of the total cohort of 186,468 approximately 2 % (n =
3677) of individuals had records of prescription stimu-
lant for ADHD during the study period. Table 1 shows
the socio-demographic profile of the stimulant and non-
stimulant groups. The age at initial stimulant use ranged
from 2–25 years with a mean age 8.7 years (SD 2.3). In-
dividuals who had stimulant were mostly male (n = 2946,
80.1 %), with non-Aboriginal parents (n = 3423, 93.1 %),
living in metropolitan areas (n = 2212, 60.2 %), and were
least disadvantaged (n = 1299, 35.3 %). Some 155
(19.5 %) individuals had at least one Aboriginal parent,
represented by only an Aboriginal father in 93 instances
(2.5 %), only an Aboriginal mother in 62 (1.7 %) and by
both parents being Aboriginal in 99 (2.7 %).
Ethnic and demographic differences in stimulant use
Results of Cox regression analysis evaluating the associa-
tions between prescription stimulant use for ADHD and
Aboriginality and other demographic characteristics are
shown in Table 2. Both univariate and multivariate
models showed that individuals with both Aboriginal
parents were two-thirds less likely (adjusted HR 0.33,
95 % CI 0.26–0.42, p < 0.001) and individuals with Abo-
riginal mothers only were one-third less likely (adjusted
HR 0.69, 95 % CI 0.53–0.90, p = 0.006) to use stimulants
than individuals of non-Aboriginals parents. The risk for
stimulant use in individuals of Aboriginal fathers was
not significantly different from individuals of non-
Aboriginal parents in either the crude or adjusted ana-
lysis. After adjusted, the association between risk for
stimulant use and maternal age was marked. Individuals
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of mothers younger than aged 20 years had a 1.5 fold
(HR 1.52, 95 % CI 1.33–1.74, p < 0.001) increased risk
for stimulant use as compared to individuals of mothers
aged 25–29 years, whereas a decreased risk was seen of
mothers aged 30–34 years (HR 0.88, 95 % CI0.80–0.96,
p = 0.007). Boys were nearly four times more likely to be
prescribed than girls (HR 3.85, 95 % CI 3.53–4.20, p <
0.001). Likewise, geographical remoteness was a strong
determinant of the outcomes with HR ranging from 0.87
(95 % CI 0.80–0.94, p < 0.001) in rural to HR 0.63 (95 %
CI 0.54–0.74, p < 0.001) in remote areas compared with
HR in metropolitan areas. Individuals with most-
disadvantage had a two-fold increased risk for stimulants
use compared to those with least socioeconomic status
(HR 2.03, 95 % CI 1.82–2.27, p < 0.001).
Comparison of stimulant use between non-Aboriginals
and Aboriginals living in metropolitan and non-
metropolitan areas
In the adjusted model, individuals with both Aboriginal
parents were 65 % less likely (HR 0.35, 95 % CI 0.25–0.49,
p < 0.001) in metropolitan, and 72 % less likely in rural
and remote areas (HR 0.28, 95 % CI 0.20–0.38, p < 0.001)
to have stimulants than individuals with non-Aboriginal
parents (Table 3). The HR was also lower in metropolitan,
(HR 0.68, 95 % CI 0.48–0.95, p = 0.03) and in non-
metropolitan areas (HR 0.66, 95 % CI 0.44–1.0, p = 0.05)
for those who had only Aboriginal mothers. A 1.6 fold
higher risk for stimulant use was seen in individuals of
mother’s younger than 20 years old (HR 1.56 95 % CI
1.24–1.97, p < 0.001) compared with mother age 25–29
years old. The higher risk for stimulant use among boys
was observed in both metropolitan (HR 3.69, 95 % CI
3.33–4.09, p < 0.001) and non-metropolitan areas (HR
4.24, 95 % CI 3.61–4.99, p < 0.001). HR was elevated by
two-fold in the most-disadvantaged group compared with
their least-disadvantaged counterparts (metropolitan –
HR 2.17, 95 % CI 1.89–2.49, p < 0.001), (non-metropol-
itan– HR 1.80, 95 % CI 1.49–2.17, p < 0.001).
Comparison of stimulant use within Aboriginal group
The fitted univariate and multivariate models for stimu-
lant use determinants in only those individuals who had
any Aboriginal parents are shown in Table 4. Aboriginal
boys were four times more likely to be prescribed than
Aboriginal girls (HR 4.08, 95 % CI 2.92–5.69, p < 0.001).
Aboriginals living in remote areas were 62 % less
likely (HR 0.38, 95 % CI 0.26–0.56, p < 0.001) to have
stimulants than their city counterparts. Mothers’ age
and socioeconomic status were not significantly asso-
ciated with stimulant use within this group. We also
fitted a multiple linear regression model to examine
the association between mean age at initial prescrip-
tion stimulants and demographic and geographic vari-
ables, but no association was observed (results attached as
Additional file 1).
Discussion
Despite increasing recognition of ADHD among Abori-
ginal children [12, 22, 23], the risk of stimulant use for
ADHD was markedly lower among individuals of Abori-
ginal parents than individuals of non-Aboriginal parents
in our study. Parents are unlikely to pursue ADHD
medication if they do not perceive ADHD as a clinical
problem [24]. Aboriginal parents who allow children
freedom to explore their environment without restric-
tions to make them physically and emotionally resilient
[25], may perceive hyperactivity and impulsivity as nor-
mal child behaviour.
Table 1 Baseline demographic characteristics of Aboriginal and











164290 (89.9) 3423 (93.1)
Both parents
Aboriginal
10737 (5.9) 99 (2.7)
Only father
Aboriginal
3955 (2.2) 93 (2.5)
Only mother
Aboriginal
3809 (2.1) 62 (1.7)
Mothers’ age at
birth
<20 11642 (6.4) 345 (9.4)
20–24 35823 (19.6) 992 (27.0)
25–29 60471 (33.1) 1157 (31.5)
30–34 53085 (29.0) 834 (22.7)
35–39 18764 (10.3) 299 (8.1)
≥40 2762 (1.5) 44 (1.2 %)
Unknown 244 (0.1 %) 6 (0.2 %)
Sex Male 92708 (50.7) 2946 (80.1)
Female 90081 (49.3) 731 (19.9)
Unknown 2 (0.01) 0
Geographical
remoteness
Metropolitan 105567 (57.8) 2212 (60.2)
Rural 40332 (22.1) 799 (21.7)
Remote 14160 (7.7) 171 (4.7)
Unknown 22732 (12.4) 495 (13.5)
Socioeconomic
disadvantage
Least disadvantaged 78304 (42.8) 1299 (35.3)
Less disadvantaged 42061 (23.0) 845 (23.0)
Little disadvantaged 17015 (9.3) 395 (10.7)
More disadvantaged 8373 (4.6) 183 (5.0)
Most disadvantaged 15467 (8.5) 489 (13.3)
Unknown 21571 (11.8) 466 (12.7)
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Aboriginal children were subject to removal from their
families historically through systematic policy of colonial
intervention, and also to a lesser extent today through
out-of-homecare programs [26, 27]. Parental separation
and early attachment deprivation is a risk factor for
ADHD in children [28]. Aboriginal parents may attribute
hyperactivity and impulsivity to child-removal-associated
trauma which has been rooted in the Aboriginal cul-
tural memory [29]. This trauma has been advanced as
a reason why treatment may appear to the Aboriginal
parents as a repetition of the colonial practices [30],
jeopardising abilities to fulfil their roles in family and
community [31].
Stimulant use was notably lower in individuals of Abo-
riginal mothers than fathers, possibly due to the fact that
Aboriginal women traditionally play a central role in
family and community, and are solely responsible for
caretaking and early child socialization [32, 33]. Con-
versely, another study reported fathers more than
mothers were associated with lower stimulant use in
non-Anglophonic Australian communities [34]. The
authors argued that fathers who were less likely to per-
ceive ADHD as a problem than mothers were the
decision-maker about child health in non-English speak-
ing communities.
We found lower risk of stimulant use among Aborigi-
nals in non-metropolitan than in metropolitan areas
likely due to geographical disparities in healthcare ser-
vice access with shortages of health-related infrastruc-
ture in rural areas in Australia [35]. Positive impact of
community support and sense of belonging on protect-
ing Aboriginal people against mental illness in both
metropolitan and remote Aboriginal communities in
Australia are documented [36, 37]. Yet, it is difficult to
measure if the influence of the community support on
mental health is greater in rural than metropolitan com-
munities. In Canada, Currie et al. [38] reported that
while Aboriginal enculturation was protective against
substance use and strengthened psychological wellbeing,
mainstream acculturation weakens the influence of cul-
tural ties and was a risk factor for substance abuse in
urban Aboriginal adults. As Aboriginal people continue to
urbanize in Australia [39], they may adopt beliefs and atti-
tudes to ADHD medication of the mainstream urban soci-
ety leading to the discrepancy in stimulant use between
metropolitan and remote Aboriginal communities here.
We made a number of other salient observations in
this study. The first confirmed the well-known gender
variation in stimulant use. Both Aboriginal and non-
Aboriginal boys had elevated risk of stimulant use
Table 2 Hazard ratios and 95 % CI of prescription stimulant medication in Aboriginal and non-Aboriginal children and adolescents
Parameter Univariate Analysis Multivariate Analysisa
HR (95 % CI) P-Value HR (95 % CI) P-Value
Parents Aboriginal status Non-Aboriginal parents 1.0 1.0
Both parents Aboriginal 0.45(0.37–0.55) <0.001 0.33(0.26–0.42) <0.001
Only father Aboriginal 1.13(0.92–1.38) 0.26 0.92(0.74–1.14) 0.45
Only mother Aboriginal 0.78(0.61–1.01) 0.059 0.69(0.53–0.90) 0.006
Mothers’ age group in years at birth <20 1.54(1.36–1.73) <0.001 1.52(1.33–1.74) <0.001
20–24 1.44(1.32–1.56) <0.001 1.42(1.30–1.56) <0.001
25–29 1.0 1.0
30–34 0.82(0.75–0.90) <0.001 0.88(0.80–0.96) 0.007
35–39 0.84(0.74–0.95) 0.006 0.90(0.79–1.03) 0.14
≥40 0.84(0.62–1.13) 0.24 0.83(0.60–1.16) 0.28
Sex Female 1.0 1.0
Male 3.83(3.53–4.15) <0.001 3.85(3.53–4.20) <0.001
Geographical remoteness Metropolitan 1.0 1.0
Rural 0.95(0.87–1.03) 0.18 0.87(0.80–0.94) <0.001
Remote 0.58(0.50–0.68) <0.001 0.63(0.54–0.74) <0.001
Socioeconomic disadvantage Least disadvantaged 1.0 1.0
Less disadvantaged 1.21(1.12–1.32) <0.001 1.19(1.09–1.30) <0.001
Little disadvantaged 1.39(1.24–1.56) <0.001 1.32(1.18–1.49) <0.001
More disadvantaged 1.31(1.12–1.53) <0.001 1.31(1.12–1.53) <0.001
Most disadvantaged 1.88(1.70–2.09) <0.001 2.03(1.82–2.27) <0.001
aAll parameters were included in the regression model so as to adjust each result for potential confounding by all other covariates
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Table 4 Hazard ratios and 95 % CI of prescription stimulant medication in Aboriginal children and adolescents
Parameter Univariate Analysis Multivariate Analysisa
HR (95 % CI) P-Value HR (95 % CI) P-Value
Mothers’ age group in years at birth <20 0.70(0.47–10.4) 0.08 0.69(0.45–1.07) 0.10
20–24 1.10(0.80–1.50) 0.56 1.20(0.85–1.69) 0.29
25–29 1.0 1.0
30–34 1.06(0.72–1.57) 0.78 1.30(0.86–1.96) 0.22
35–39 0.98(0.54–1.77) 0.94 1.25(0.68–2.28) 0.48
≥40 0.46(0.06–3.33) 0.44 0.60(0.08–4.33) 0.61
Sex Female 1.0 1.0
Male 4.51(3.27–6.23) <0.001 4.08(2.92–5.69) <0.001
Geographical remoteness Metropolitan 1.0 1.0
Rural 0.83(0.61–1.13) 0.23 0.82(0.60–1.12) 0.20
Remote 0.39(0.27–0.58) <0.001 0.38(0.26–0.56) <0.001
Socioeconomic disadvantage Least disadvantaged 1.0 1.0
Less disadvantaged 1.05(0.68–1.63) 0.82 1.15(0.74–1.78) 0.53
Little disadvantaged 1.25(0.78–1.99) 0.35 1.29(0.81–2.05) 0.29
More disadvantaged 1.10(0.65–1.88) 0.71 1.26(0.74–2.16) 0.39
Most disadvantaged 1.14(0.76–1.72) 0.53 1.40(0.92–2.12) 0.12
aAll parameters were included in the regression model so as to adjust each result for potential confounding by all other covariates
Table 3 Comparison of stimulant medication in Aboriginal and non-Aboriginal children by metropolitan and non-metropolitan
areas
Parameter Multivariate Analysis Multivariate Analysisa
Metro Non-Metro
HR (95 % CI) P-Value HR (95 % CI) P-Value
Parents Aboriginal status Non-Aboriginal parents 1.0 1.0
Both parents Aboriginal 0.35(0.25–0.49) <0.001 0.28(0.20–0.38) <0.001
Only father Aboriginal 0.96(0.73–1.26) 0.76 0.8(0.55–1.17) 0.26
Only mother Aboriginal 0.68(0.48–0.95) 0.03 0.66(0.44–1.0) 0.051
Mothers’ age group in years at birth <20 1.51(1.28–1.78) <0.001 1.56(1.24–1.97) <0.001
20–24 1.48(1.33–1.66) <0.001 1.30(1.10–1.53) 0.002
25–29 1.0 1.0
30–34 0.89(0.79–1.00) 0.04 0.85(0.71–1.01) 0.07
35–39 0.85(0.73–1.00) 0.57 1.06(0.82–1.35) 0.67
≥40 0.78(0.52–1.16) 0.22 1.00(0.55–1.82) 0.99
Sex Female 1.0 1.0
Male 3.69(3.33–4.09) <0.001 4.24(3.61–4.99) <0.001
Socioeconomic disadvantage Least disadvantaged 1.0 1.0
Less disadvantaged 1.19(1.07–1.33) <0.001 1.15(0.98–1.35) 0.10
Little disadvantaged 1.33(1.16–1.53) <0.001 1.28(1.04–1.58) 0.02
More disadvantaged 1.4(1.16–1.69) <0.001 1.13(0.85–1.49) 0.41
Most disadvantaged 2.17(1.89–2.49) <0.001 1.80(1.49–2.17) <0.001
aAll parameters were included in the regression model so as to adjust each result for potential confounding by all other covariates
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possibly due to the fact that boys commonly manifest
hyperactivity and impulsivity [40] which may closely
entwine with heuristics and gender stereotypes influ-
encing referral [41] and diagnose [42]. Secondly, the
association between young maternal age and increased
stimulant use risk is well established [43–45]. A high
level of maternal depression, smoking and substance
use during pregnancy has been reported as risk fac-
tors for ADHD in children [44, 45]. This association
however was not marked in Aboriginal groups here,
and may need further research. Thirdly, associations
between socioeconomic hardship and increased stimu-
lant use was in line with previous Australian studies
[34, 40]. While a high prevalence of ADHD in mar-
ginalised children is well established [10, 46], a large
proportion of Australian children living in poverty
were reported as being treated without meeting the
ADHD diagnosis criteria [47, 48]. Hence, disadvan-
taged children who are more likely to be diagnosed
with ADHD represent an important public health
issue. Yet our findings of no association between dis-
advantage and stimulant use within Aboriginal groups
is novel, however different interpretations exist and
further investigation is warranted. One possibility is
that within the Aboriginal population, social disadvan-
tage correlates with ADHD symptoms and with a ten-
dency not to receive treatment. Community support
and cultural bond which have been shown to buffer
mental and behavioural problems for marginalised
people [49] could be another explanation.
Some limitations need to be considered when inter-
preting our results. The datasets did not permit identifi-
cation of individuals diagnosed with ADHD but not
prescribed stimulants. It would have been useful to
examine differences between diagnosis rates and stimu-
lant treatment in Aboriginal children to investigate the
likelihood of stimulant over- or under-prescribing. In
order to correctly identify Aboriginal people we triangu-
lated information from two data sources; yet, it is still
possible that Aboriginality is under-reported or misre-
ported. It is also possible that our results were affected
by unmeasured and, as yet, unidentified confounders.
Conclusion
Lower stimulant use for ADHD in children and adoles-
cents of Aboriginal parents in our study suggests either
Aboriginal parent perceive ADHD symptoms as normal
child behaviour, have a negative attitude towards medi-
cation, or cultural competency provides a coping mech-
anism to make the ADHD symptoms functional.
Alternatively, Aboriginal children who would stand to
benefit from ADHD medication may face barriers to
access. Aboriginal children should be protected from
misdiagnosis and over-diagnosis; however, great care
should be taken to ensure full access to appropriate ser-
vices when required. A better understanding of Aborigi-
nal perceptions of ADHD and stimulant treatment is
crucial to identify vulnerabilities and develop targeted
interventions and policy that account for social factors
and align with Aboriginal culture to provide optimal
care. We suggest two avenues for future research exam-
ining ADHD prevalence in Aboriginal children with nar-
rowing of focus: first, for the rate of ADHD diagnosis
and stimulant treatment to be investigated; and second,
qualitative research to explore Aboriginal perception
towards ADHD and stimulant treatment.
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